Acetrizoic Acid

Summary

Acetrizoic Acid (CHEMBL1201327) is an approved small molecule (ATC V08AA07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA07
• Chemistry: 556.86 Da · C9H6I3NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201327
Name	Acetrizoic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6806
ATC	V08AA07
Molecular formula	C9H6I3NO3
Molecular weight	556.86
InChIKey	GNOGSFBXBWBTIG-UHFFFAOYSA-N

SMILES: CC(=O)NC1=C(C=C(C(=C1I)C(=O)O)I)I

IUPAC name: 3-acetamido-2,4,6-triiodobenzoic acid

Also known as: Acetrizoate, Acetrizoic acid, NSC-758681, Urokonic acid, SID26748914, ACETRIAZOIC ACID, SID144204976, SID170465154, ACETRIZOIC ACID, Acetrizoic_acid, SODIUM ACETRIZOATE

Parent form; salt/anhydrous children: CHEMBL1201045

Patent coverage: 269 distinct patent families (758 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 748 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).